Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.